Literature DB >> 28326436

Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden.

Janusch Blautzik1, Matthias Brendel1, Julia Sauerbeck1, Sebastian Kotz1, Franziska Scheiwein1, Peter Bartenstein1, John Seibyl2, Axel Rominger3.   

Abstract

Relative quantitative analysis of amyloid plaque burden in Alzheimer's disease (AD) patients can be reported as standardized uptake value ratio (SUVR) from positron emission tomography (PET). Here, the SUVR is the ratio of the mean amyloid radioligand retention in a composite (COMP) neocortical volume of interest (VOI) to that in a reference VOI, such as the cerebellum, brainstem (BST)/pons, or white matter (WM). Some longitudinal PET investigations show that the rate of amyloid accumulation to follow-up has an inverted U relationship with baseline amyloid SUVR relative to cerebellar or brainstem/pons reference VOIs. The corresponding association with SUVR relative to WM is unknown. To test the possible benefits of WM normalization, we analyzed [18F]-AV45 PET data from 404 subjects in the AD Neuroimaging Initiative (ADNI) database at baseline and 2-year follow-up (144 cognitively normal controls, 225 patients with mild cognitive impairment, and 35 AD patients). Reference regions included subcortical WM as well as conventional cerebellar gray matter (CBL), and BST. We tested associations between each subject's inter-session change (∆) of SUVR and their baseline SUVR by applying linear, logarithmic, and quadratic regression analyses. Unscaled standardized uptake values (SUVs) were correlated between VOIs at baseline and follow-up, and within VOIs in the longitudinal run. The association between ∆SUVR and baseline SUVR relative to WM reference was best described by an inverted U-shaped function. Correlation analyses demonstrated a high regional and temporal correlation between COMP and WM VOI SUVs. For WM normalization, we confirm that the rate of amyloid accumulation over time follows an inverted U-shaped function of baseline amyloid burden. Reference region selection, however, has substantial effects on SUVR results. This reflects the extent of covariance between SUVs in the COMP VOI and those in the various reference VOIs. We speculate that PET labeling of amyloid deposition within target regions is partially confounded by effects of longitudinal changes of cerebral blood flow (CBF) on tracer delivery. Indeed, CBF may be the leading factor influencing longitudinal SUV changes. We suggest that SUVR relative to WM may be more robust to changes in CBF, and thus fitter for sensitive detection of amyloid accumulation in intervention studies.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-PET; Quantification; Reference region; SUVR

Mesh:

Substances:

Year:  2017        PMID: 28326436     DOI: 10.1007/s00259-017-3666-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Authors:  Nicolas Villain; Gaël Chételat; Blandine Grassiot; Pierrick Bourgeat; Gareth Jones; Kathryn A Ellis; David Ames; Ralph N Martins; Francis Eustache; Olivier Salvado; Colin L Masters; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2012-05-23       Impact factor: 13.501

2.  Surrogate markers for cerebral blood flow correlate with [¹⁸F]-fallypride binding potential at dopamine D(2/3) receptors in human striatum.

Authors:  Paul Cumming; Guoming Xiong; Christian la Fougère; Axel Rominger; Peter Bartenstein; Hans-Georg Buchholz; Markus Piel; Frank Rösch; Gerhard Gründer; Ingo Vernaleken
Journal:  Synapse       Date:  2013-01-12       Impact factor: 2.562

3.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Authors:  Henryk Barthel; Hermann-Josef Gertz; Stefan Dresel; Oliver Peters; Peter Bartenstein; Katharina Buerger; Florian Hiemeyer; Sabine M Wittemer-Rump; John Seibyl; Cornelia Reininger; Osama Sabri
Journal:  Lancet Neurol       Date:  2011-04-08       Impact factor: 44.182

4.  Decreased cerebral blood flow and prognosis of Alzheimer's disease: a multicenter HMPAO-SPECT study.

Authors:  Tsunehiko Nishimura; Kazuo Hashikawa; Hidenao Fukuyama; Takao Kubota; Shin Kitamura; Hiroshi Matsuda; Haruo Hanyu; Hidehiko Nabatame; Naohiko Oku; Hirotaka Tanabe; Yasuo Kuwabara; Seishi Jinnouchi; Atsushi Kubol
Journal:  Ann Nucl Med       Date:  2007-01       Impact factor: 2.668

5.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

6.  Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects.

Authors:  Federico Nemmi; Laure Saint-Aubert; Djilali Adel; Anne-Sophie Salabert; Jérémie Pariente; Emmanuel J Barbeau; Pierre Payoux; Patrice Péran
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-27       Impact factor: 9.236

7.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

8.  Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern?

Authors:  Jitka Sojkova; Lori Beason-Held; Yun Zhou; Yang An; Michael A Kraut; Weigo Ye; Luigi Ferrucci; Chester A Mathis; William E Klunk; Dean F Wong; Susan M Resnick
Journal:  J Nucl Med       Date:  2008-08-14       Impact factor: 10.057

9.  Longitudinal amyloid imaging using 11C-PiB: methodologic considerations.

Authors:  Bart N M van Berckel; Rik Ossenkoppele; Nelleke Tolboom; Maqsood Yaqub; Jessica C Foster-Dingley; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Ronald Boellaard
Journal:  J Nucl Med       Date:  2013-08-12       Impact factor: 10.057

10.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Authors:  Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

View more
  7 in total

1.  TSPO PET Using [18F]PBR111 Reveals Persistent Neuroinflammation Following Acute Diisopropylfluorophosphate Intoxication in the Rat.

Authors:  Brad A Hobson; Douglas J Rowland; Sílvia Sisó; Michelle A Guignet; Zachary T Harmany; Suren B Bandara; Naomi Saito; Danielle J Harvey; Donald A Bruun; Joel R Garbow; Abhijit J Chaudhari; Pamela J Lein
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

2.  A 4-Year Follow-Up of Subjects with Visually Equivocal Amyloid Positron Emission Tomography Findings from the Alzheimer's Disease Neuroimaging Initiative Cohort.

Authors:  Minyoung Oh; Minjung Seo; Sun Young Oh; Heeyoung Kim; Byung Wook Choi; Jungsu S Oh; Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2021-03-04

3.  Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies.

Authors:  Bart M de Vries; Tessa Timmers; Emma E Wolters; Rik Ossenkoppele; Sander C J Verfaillie; Robert C Schuit; Philip Scheltens; Wiesje M van der Flier; Albert D Windhorst; Bart N M van Berckel; Ronald Boellaard; Sandeep S V Golla
Journal:  Mol Imaging Biol       Date:  2021-01-14       Impact factor: 3.488

4.  Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging.

Authors:  Julie Ottoy; Ellis Niemantsverdriet; Jeroen Verhaeghe; Ellen De Roeck; Hanne Struyfs; Charisse Somers; Leonie Wyffels; Sarah Ceyssens; Sara Van Mossevelde; Tobi Van den Bossche; Christine Van Broeckhoven; Annemie Ribbens; Maria Bjerke; Sigrid Stroobants; Sebastiaan Engelborghs; Steven Staelens
Journal:  Neuroimage Clin       Date:  2019-03-13       Impact factor: 4.881

5.  Spill-in counts in the quantification of 18F-florbetapir on Aβ-negative subjects: the effect of including white matter in the reference region.

Authors:  Francisco Javier López-González; Alexis Moscoso; Nikos Efthimiou; Anxo Fernández-Ferreiro; Manuel Piñeiro-Fiel; Stephen J Archibald; Pablo Aguiar; Jesús Silva-Rodríguez
Journal:  EJNMMI Phys       Date:  2019-12-19

6.  Tracer-specific reference tissues selection improves detection of 18 F-FDG, 18 F-florbetapir, and 18 F-flortaucipir PET SUVR changes in Alzheimer's disease.

Authors:  Yanxiao Li; Yee Ling Ng; Manish D Paranjpe; Qi Ge; Fengyun Gu; Panlong Li; Shaozhen Yan; Jie Lu; Xiuying Wang; Yun Zhou
Journal:  Hum Brain Mapp       Date:  2022-02-15       Impact factor: 5.038

7.  A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease.

Authors:  Julie Ottoy; Jeroen Verhaeghe; Ellis Niemantsverdriet; Sebastiaan Engelborghs; Sigrid Stroobants; Steven Staelens
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.